Drug interactions
Doxorubicin liposomal + Rolapitant
Severity: Minor
Doxorubicin liposomal and Rolapitant: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Rolapitant may increase exposure to doxorubicin through CYP2D6 inhibition, though CYP2D6 is a minor pathway for doxorubicin and liposomal encapsulation alters its disposition. The clinical significance is uncertain but toxicity such as myelosuppression and cardiotoxicity could be increased.
What this interaction means in plain words
Doxorubicin liposomal and Rolapitant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Rolapitant inhibits CYP2D6, a minor metabolic route for doxorubicin.
What to do
No routine dose change; monitor blood counts and cardiac status according to standard doxorubicin practice.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Doxorubicin liposomal and Rolapitant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Rolapitant
- Pimozide + Rolapitant Contraindicated
- Rolapitant + Thioridazine Contraindicated
- Atomoxetine + Rolapitant Major
- Deutetrabenazine + Rolapitant Major
- Eliglustat + Rolapitant Major
- Flecainide + Rolapitant Major
Frequently asked questions
Can I take Doxorubicin liposomal with Rolapitant?
MediHelp rates the interaction as minor. Doxorubicin liposomal and Rolapitant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Rolapitant may increase exposure to doxorubicin through CYP2D6 inhibition, though CYP2D6 is a minor pathway for doxorubicin and liposomal encapsulation alters its disposition. The clinical significance is uncertain but toxicity such as myelosuppression and cardiotoxicity could be increased.
How serious is the interaction between Doxorubicin liposomal and Rolapitant?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine dose change; monitor blood counts and cardiac status according to standard doxorubicin practice.
What other medicines interact with Rolapitant?
MediHelp also lists interactions of Rolapitant with, for example, Pimozide, Thioridazine, Atomoxetine. The full list is on the Rolapitant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
